was 2.4% in the ganirelix group and 5.9% in the reference Puregon ® ). The study was designed as a non-inferiority group. The results of this study support a safe, short and study using a long protocol of buserelin (intranasal) and convenient treatment regimen of ganirelix, resulting in a rFSH as a reference treatment. A total of 730 subjects was good clinical outcome for patients undergoing ovarian randomized in a treatment ratio of 2:1 (ganirelix:buserelin) stimulation for IVF or ICSI. using an interactive voice response system which stratified Key words: buserelin/ganirelix/GnRH agonist/GnRH antagonfor age, type of infertility and planned fertilization procedist/ICSI/IVF/ovarian stimulation/recombinant FSH ure [IVF or intracytoplasmic sperm injection (ICSI)]. The median duration of GnRH analogue treatment was 5 days in the ganirelix group and 26 days in the buserelin group, whereas the median total rFSH dose was 1500 IU and 1800 IU respectively. In addition, in the ganirelix group Introduction the mean duration of stimulation was 1 day shorter.
Introduction the mean duration of stimulation was 1 day shorter.
Ganirelix is the active ingredient of Orgalutran ® and Antagon ™ , During ganirelix treatment the incidence of LH rises a gonadotrophin-releasing hormone (GnRH) antagonist pre-(LH ≥10 IU/l) was 2.8% versus 1.3% during rFSH stimulaparation developed for the prevention of premature LH surges tion in the buserelin group. On the day of triggering in women undergoing ovarian stimulation. In comparison with ovulation by human chorionic gonadotrophin (HCG), the native GnRH, ganirelix has substituted amino acids at positions mean number of follicles ≥11 mm diameter was 10.7 and 1, 2, 3, 6, 8 and 10, which results in a potent antagonist with 11.8, and the median serum oestradiol concentrations were only minimal histamine-releasing properties (Rabinovici et al., 1190 pg/ml and 1700 pg/ml in the ganirelix and buserelin 1992; Nelson et al., 1995) and high aqueous solubility. The groups respectively. The mean number of oocytes per latter property is reflected by the high absolute bioavailability retrieval was 9.1 and 10.4 respectively, whereas the mean (F) of ganirelix being more than 90% after s.c. injection (Oberyé et al., 1999a) . In current practice, GnRH agonists are used to suppress *T.Åbyholm (Kvinneklinikken, Rikshospitalet, Oslo, Norway); D.Barlow (John Radcliffe Hospital, Oxford, UK); P.Devroey endogenous gonadotrophins during ovarian stimulation (Academic Hospital, Free University Brussels, Brussels, Belgium); (Loumaye, 1990) . However, agonists initially stimulate the after each injection (Oberyé et al., 1999b) . Moreover, after discontinuation, a rapid recovery of pituitary function (Gordon et al., 1990) was observed, also due to the relative short elimination half-life (about 13 h) of ganirelix. The additional anticipated advantages of antagonist treatment in ovarian stimulation programmes are a reduction of the use of gonadotrophins, a lower risk for developing ovarian hyperstimulation syndrome (OHSS), and the ability to use a bolus injection of a GnRH agonist to trigger a midcycle LH surge for final follicular maturation (Olivennes et al., 1996) . Moreover, in cases of multiple follicles and excessively high oestradiol concentrations, the use of GnRH agonist instead of human chorionic gonadotrophin (HCG) is thought to prevent the clinical manifestation of OHSS (Itskovitz et al., 1991 Main, Germany) in a ratio of 2:1. To improve balance, a minimization and 1 mg (Diedrich et al., 1994; Felberbaum et al., 1995) , but method was used for randomizing patients to treatment (Treasure and finally the lowest effective daily dose of cetrorelix appeared MacRae, 1999) , stratifying for centre age, for primary or secondary to be 0.25 mg (Albano et al., 1997 (Albano et al., , 1999 . To select the infertility, and for IVF or ICSI.
minimal effective daily dose of ganirelix, a multicentre, double-A diagrammatic representation of the applied treatment regimens is shown in Figure 1 . Injections of rFSH (Puregon ® ; NV Organon) blind, randomized, dose-finding study was performed in 333 and ganirelix were given in the morning. In the ganirelix group, women including six different dosages ranging between 0.0625 treatment with rFSH was started in patients on day 2 or 3 of the and 2 mg (Ganirelix dose-finding study group, 1998; Itskovitzmenstrual cycle by a once-daily s.c. injection. After 5 days of rFSH Eldor et al., 1998) . In this study, patients were treated with a treatment, ganirelix treatment was started by daily s.c. administration fixed dose of 150 IU rFSH for 5 days before starting ganirelix.
in the upper leg. Ganirelix treatment was continued up to and
The study revealed that a daily dose of 0.25 mg ganirelix including the day of HCG administration.
prevented LH from rising above 10 IU/l during stimulation, In the buserelin reference group, pretreatment with buserelin was and resulted in a good clinical outcome, i.e. the ongoing started in the midluteal phase (cycle day 21-24) with a daily dose of pregnancy rate was 34% per attempt (23/68) and 37% per 0.6 mg intranasally (four puffs per day). Ovarian stimulation was transfer (23/62). Moreover, as in other studies (Fujimoto et al., started after 2 weeks if pituitary down-regulation was established 1997; Oberyé et al., 1999b) , serum ganirelix concentrations (serum oestradiol concentration Ͻ50 pg/ml or Ͻ200 pmol/l). In case down-regulation was not achieved after 2 weeks, stimulation was increased in a linear dose-proportional manner, and serum LH postponed and the daily dose of buserelin was doubled to 1.2 mg. decreased in a dose-proportional manner, indicating that the The dose of buserelin at which down-regulation was established (0.6 degree of pituitary suppression can be adjusted by changing or 1.2 mg) was continued up to the day of HCG. If down-regulation the ganirelix dose.
with buserelin was not achieved within 4 weeks, treatment was
In the current study the efficacy and safety of a multiplediscontinued.
dose regimen administering 0.25 mg ganirelix daily was
In both treatment groups, ovarian stimulation was started with a assessed in a randomized study in women undergoing ovarian fixed daily dose of 150 IU rFSH for the first five treatment days. stimulation with rFSH for IVF or intracytoplasmic sperm From day 6 onwards, the dose of rFSH was adapted depending on injection (ICSI).
the ovarian response as monitored via ultrasonography. On the day of HCG, rFSH was not administered.
HCG (10 000 IU, Pregnyl ® ; NV Organon) was administered when
Materials and methods
at least three follicles of ജ17 mm diameter were observed, and 30-36 h thereafter oocyte retrieval was performed. Oocyte retrieval was Patients followed by IVF or ICSI, and no more than three embryos were to A total of 730 patients, for whom ovarian stimulation and IVF or be replaced 2-5 days thereafter. Luteal phase support was given ICSI was indicated, was screened and randomized in this study. In according to the clinics' routine practice, and was started no later total, 20 IVF centres in 10 European countries participated, and the than the day of embryo transfer. number of randomized patients per centre ranged from 11 to 60. Main inclusion criteria were: age at least 18 years but not older than Assessments 39 years; body mass index (BMI) between 18 and 29 kg/m 2 ; regular
In the ganirelix group prior to the start of rFSH, and in the buserelin menstrual cycle, ranging from 24 to 35 days. group prior to the start of buserelin, an HCG test was to be performed Study design to exclude pregnancy. When bleeding did not occur within 2 weeks after starting buserelin treatment, an additional HCG test was perThis trial was a phase III, multi-centre, open-label, randomized study to assess the efficacy and safety of the GnRH-antagonist ganirelix formed. Just before the first injection of rFSH, a blood sample was taken for hormone assessment and ultrasonography (USS) was The study was designed as a non-inferiority trial to test whether the combination of efficacy, safety and convenience of ganirelix treatment a Values are mean Ϯ SD.
was clinically equivalent to the current care, i.e. GnRH agonist treatment in a long protocol. As a large previous study with Puregon and intranasal buserelin in a long protocol had an excellent clinical and for whom spare embryos were cryopreserved. By June 1999, 53 outcome (Out et al., 1995) , this regimen was selected as the reference of these patients had had at least one embryo transfer using thawed treatment in the current study. Data from the intent-to-treat (ITT) embryos. The outcome of these first freeze-thaw cycles is presented. group were used for efficacy analysis, and data from the all-subjectstreated (AST) group were used for safety analysis. The ITT group Safety analysis and the AST group consisted of all patients randomized who started Analysis was performed by means of frequency distributions of the treatment. Patients in the ITT group were grouped according to the incidence of adverse events, local tolerance outcome, clinically treatment they should have received by randomization, whereas significant abnormal laboratory values and vital signs. For patients patients in the AST group were grouped according to the actual treated with the ganirelix regimen, analysed data included all days treatment they received.
of stimulation, thus also the first 5 days of rFSH treatment when patients were not yet exposed to ganirelix. Efficacy analysis A total of 701 subjects started treatment with rFSH or buserelin and was included in the ITT group. Of the treated subjects, 463 were insemination instead of oocyte retrieval. In the buserelin group, seven patients (3.0%) were discontinued before starting rFSH respectively. The total amount of rFSH administered was in LH (IU/l) 1.6 (Ͻ0.6-6.9) 1.5 (Ͻ0.6-4.4) Oestradiol (pg/ml) 1190 (373-3105) 1700 total 1500 (900-5400) IU and 1800 (900-6450) IU, and the Progesterone (ng/ml) 0.7 (0.4-1.6) 0.7 (0.4-1.6) median daily dose was 150 IU/day and 178 IU/day in the Oestradiol/follicle (pg/ml) 111 144 ganirelix and buserelin groups respectively.
a Includes one patient who received HCG because of premature luteinization.
LH rises (ജ10 IU/l) before and during ganirelix treatment
Early LH rises at day 6 of stimulation, before the first ganirelix early or late rise of serum LH after confirmation of an early clinical pregnancy. administration, were observed in 20 patients (4.3%). In these patients serum LH values ranged between 10.4 and 33.4 IU/l Follicle growth and concomitant rises of serum progesterone Ͼ1 ng/ml were observed in seven out of these 20 patients. On day 6 of The mean (Ϯ SD) number of follicles ജ11 mm diameter measured on days 6, 8 and 10 of stimulation for patients with stimulation, this subset of patients had on average 6.8 follicles ജ11 mm diameter, and their median serum oestradiol concenat least 9 days of stimulation are presented in Figure 2 . The number and size of follicles measured at the day of HCG tration was 856 (range 348-1900) pg/ml, indicating that most of these patients were high responders. Due to initiation of administration are summarized in Table III .
Comparison of the number and size of growing follicles ganirelix treatment, endogenous LH rises were effectively cutdown in all 20 patients. Out of the 20 patients, 19 had embryo indicates a different follicle growth pattern in the ganirelix group than in the buserelin group. At day 6 of stimulation, transfer, and in three patients an ongoing pregnancy was established.
after 5 days of 150 IU rFSH per day, absence of follicular growth (no follicles ജ11 mm diameter) was observed in 13.2% After the day of the first ganirelix injection, 13 women (2.8%) had an LH value ജ10 IU/l. Peak LH values ranged of patients treated with the ganirelix regimen, whereas this incidence was 31.5% in the buserelin reference group. Accordbetween 10.1 and 58.1 IU/l, and concomitant rises (Ͼ1 ng/ml) of serum progesterone were observed in six patients ingly, initial follicular growth appeared to be more rapid in the ganirelix group than in the buserelin group, as indicated (1.5%). Seven patients were discontinued before embryo transfer, and none of the other patients became pregnant. In the by the mean number of follicles ജ11 mm diameter on day 6 of stimulation (4.7 versus 3.0; Figure 2 ). On day 8 of buserelin group, three patients (1.3%) had an LH rise to ജ10 IU/l during stimulation. Of these, one patient was discontinued stimulation, the difference between the treatment groups was less apparent, and on the day of HCG the opposite was and one patient became pregnant.
Miscarriage did not occur in any of the patients with an observed in that the number of follicles ജ11 mm was smaller in the ganirelix group than in the buserelin group (10.7 versus group than in the buserelin group, whereas on the day of HCG (see Table III ) the opposite was observed, with serum oestradiol 11.8). Comparison of follicle sizes between the two treatment groups indicates that this difference was mainly due to fewer concentration being about 500 pg/ml lower in the ganirelix group than in the buserelin group (1190 versus 1700 pg/ml). small follicles in the ganirelix group (Table III) , as also reflected by the comparable mean number of follicles ജ17 mm Finally, serum oestradiol content per follicle (ജ11 mm) was lower in the ganirelix group than in the buserelin group. at the day of HCG administration (4.9 versus 5.2).
Individual serum LH values measured on day 6 and measured Serum hormone concentrations on the day of HCG were plotted in Figure 4 . Comparison of the predose values in the ganirelix group with LH values Median serum FSH, LH, oestradiol and progesterone concentrations measured at days 1, 6, 8 and 10 of stimulation for measured during down-regulation with buserelin, indicates a larger variability in the ganirelix group. A possible relationship patients with at least 9 days of stimulation are presented in Figure 3 . At the start of rFSH stimulation (day 1), serum between serum LH and pregnancy outcome (Figure 4 ) or between serum oestradiol and pregnancy outcome (data not hormone concentrations were higher in the ganirelix group than in the buserelin group, and represented normal levels as shown) was not revealed. measured at day 2 to 3 of the menstrual cycle and after Treatment outcome pituitary down-regulation respectively. On day 6 of stimulation, serum FSH and LH concentrations had become similar in both
The mean number of oocytes recovered, their quality and the mean number of embryos obtained and their quality in each treatment groups, probably due to a negative feedback by initial rising oestradiol concentrations in the ganirelix group. treatment group are given in Table IV . In comparison with buserelin treatment, ganirelix treatment resulted in one preovuMedian serum oestradiol concentrations rose from 38 pg/ml on day 1 to 358 pg/ml on day 6 of stimulation in the ganirelix latory follicle less (see above) and, as a consequence, one cumulus-oocyte complex less was recovered at oocyte group, and from 19 pg/ml to 160 pg/ml in the buserelin group. This increase was in accordance with the number of growing retrieval. The estimated treatment difference was -1.0 oocyte (lower 97.5% confidence limit -1.8) which was within the follicles in each group. From day 6 to the day of HCG, serum FSH increased by 0.5 IU/l in the ganirelix group and by 1 IU/l equivalence margin of -3 oocytes. In total, 357 patients had IVF and 291 patients had ICSI, in the buserelin group. Predose concentrations of serum LH in patients treated with ganirelix were comparable with those whereas 10 patients had both IVF and ICSI (1.5 versus 1.3% in the ganirelix and buserelin groups respectively). The mean measured in the buserelin group. After day 6 of stimulation up to the day of HCG, serum oestradiol concentrations followed (Ϯ SD) number of metaphase II oocytes recovered in ICSI patients was 83% in each group, i.e. 7.1 Ϯ 4.2 versus 8.5 Ϯ the pattern of follicular growth in that on day 8 the oestradiol concentrations were only 128 pg/ml higher in the ganirelix 5.2, and the overall fertilization rate was 62.1% in each group. shown in Table V . Although a similar number of embryos was replaced in each group, the implantation rate (number of gestational sacs divided by the number of replaced embryos) was relatively lower in the ganirelix group (15.7 versus 21.8%), whereas the miscarriage rate per clinical pregnancy was comparable (12.0 versus 13.9%). Accordingly, the vital and ongoing pregnancy rate tended to be lower in the ganirelix group than in the buserelin group. For the ITT group, the ongoing pregnancy rate per attempt was 20.3% in the ganirelix group and 25.7% in the buserelin group (including one spontaneous pregnancy in the buserelin group). The estimated differ- site, this difference ranged from 26.3% in favour of ganirelix to 28.6% in favour of buserelin. The ongoing pregnancy rate Table IV . Number of cumulus-oocytes complexes recovered per attempt per attempt for patients (n ϭ 337) treated at study sites (n ϭ and per oocyte retrieval, number and quality of embryos obtained, and 10) that had previous experience with the ganirelix regimen number of transferred embryos. Values are presented as mean Ϯ SD was similar, i.e. 24.2% in the ganirelix group and 23.6% in the buserelin group, whereas this rate was respectively 16.5
Ganirelix Buserelin and 27.5% for patients (n ϭ 363) treated in study sites (n ϭ Cumulus-oocyte complexes/attempt n ϭ 463 n ϭ 238 10) that had applied the ganirelix regimen for the first time. in the buserelin group.
Cumulus-oocyte complexes/retrieval n ϭ 440 n ϭ 221 9.1 Ϯ 5.4 10.4 Ϯ 5.8
Outcome of subsequent freeze-thaw cycles
Embryos n ϭ 463 n ϭ 238 Total 6.0 Ϯ 4.5 7.1 Ϯ 5.2
The mean (Ϯ SD) number of embryos frozen was 1.1 Ϯ 2.3
Good quality 3.3 Ϯ 3.0 3.5 Ϯ 3.2 and 1.3 Ϯ 2.5 in the ganirelix and buserelin groups respectively. The first frozen-thawed embryo cycles (n ϭ 53) performed Replaced 2.2 Ϯ 0.6 2.2 Ϯ 0.6 within one year after study completion resulted in three ICSI ϭ intracytoplasmic sperm injection.
miscarriages, one induced abortion and 10 ongoing pregnancies (12-16 weeks after embryo transfer). Seven pregnancies In addition, the number of good quality embryos obtained was (20.0%) were established in patients previously treated with comparable between the groups, and the estimated treatment ganirelix, and three pregnancies (16.7%) were established in difference was only -0.1 embryo (lower 97.5% confidence patients treated with buserelin. The overall ongoing pregnancy limit -0.4). At transfer, in each group a mean of 2.2 embryos rate was 18.9% (see Table VI ). were replaced, including a mean of 2.0 and 1.9 good quality Safety and tolerance embryos in the ganirelix and buserelin groups respectively.
The clinical outcome of all patients receiving embryo The number of subjects who experienced at least one adverse experience was 125 (26.9%, i.e. 125/465) in the ganirelix transfer, expressed per attempt and per embryo transfer, is agonists. In addition to its convenience, the regimen appeared lation. In this efficacy trial, ganirelix treatment was started on group, and 74 (31.4%, i.e. 74/236) in the buserelin group. day 6 of stimulation, since the previous dose-finding study The most frequently reported experiences were headache, (Ganirelix dose-finding study group, 1998) demonstrated that abdominal pain (gynaecological), OHSS and miscarriages.
during the first days of stimulation, median serum LH concenTreatment discontinuation because of an adverse experience trations decrease and nadir LH concentrations are reached at occurred for one patient in the ganirelix group (0.2%) due to day 5 of stimulation. This initial suppression of endogenous the risk for developing OHSS, and for one patient (0.4%) in LH is thought to be established by a negative feedback the buserelin group because of spontaneous ovulation before of rising oestradiol concentrations during the first days of oocyte retrieval. The number of subjects with possible or stimulation. When follicular growth is progressing and oestraprobable drug-related experiences was 11 (2.4%) in the ganidiol concentrations become as high as in the late follicular relix group, and nine (3.8%) in the buserelin group. In the phase of the normal menstrual cycle, then the reverse occurs ganirelix group, 18 patients (3.9%) were hospitalized because and the risk for a premature LH surge becomes imminent of an adverse experience, i.e. ectopic pregnancy (n ϭ 4), (Filicori et al., 1986 ). In the current study, early LH rises OHSS (n ϭ 4), miscarriage (n ϭ 6), threatening abortion (n ϭ before the first ganirelix administration occurred in 20 patients 1), hyperemesis (n ϭ 1), urinary retention (n ϭ 1) and who were high responders, i.e. stimulation resulted in more abdominal pain (gynaecological) (n ϭ 1). In the buserelin rapid initial follicular growth and in a more pronounced rise group, 11 patients (4.6%) were hospitalized because of ectopic of serum oestradiol as compared with the overall treatment pregnancy (n ϭ 1), OHSS (n ϭ 6 including 1 case of enteritis) group. Even though the clinical outcome of this small subset and miscarriage (n ϭ 4). All these adverse experiences were of patients was good, early LH rises may be prevented by indicated as not, or unlikely to be, drug-related.
starting ganirelix treatment on day 5 instead of day 6 of The incidence of OHSS was two-fold lower in the ganirelix stimulation. On the other hand, 13.2% of all patients did not group than in the buserelin group. Eleven subjects (2.4%) in show any follicles ജ11 mm diameter at day 6 of stimulation; the ganirelix group and 14 subjects in the buserelin group in these lower responders exposure to ganirelix may be limited (5.9%) experienced signs and symptoms related to OHSS. For by delaying the start of treatment up to the moment of actual two pregnant patients in the ganirelix group OHSS was graded follicle growth. as severe; all other cases were of moderate or mild intensity.
In the current study, duration of treatment was short, i.e. on The local tolerance outcome indicated that ganirelix adminisaverage 9 days with rFSH including 5 days of ganirelix tered daily by the s.c. route was well tolerated. The percentage treatment. Since initial growth of follicles was more rapid and of patients with at least one moderate or severe local tolerance endogenous FSH concentrations were only partly suppressed reaction (skin redness, swelling, bruising, pain or itching) (during the late follicular phase), the duration of rFSH treatment during ganirelix treatment was 16.6, 2.0 and 2.7%, at 1, 4 and was one day shorter and the amount of rFSH required was 24 h after the injection respectively. Most frequently reported lower in the ganirelix group. Since the number of subjects were moderate or severe skin redness (9.5%) or swelling without any follicles ജ11 mm diameter on day 6 of stimulation (9.5%) at 1 h after injection, but by 4 h after injection these was twice as high in the long protocol of buserelin, the ganirelix reactions had mostly disappeared. At 24 h after injection, regimen might be of special benefit for poor-responders, who bruising (moderate or severe) was most frequently reported are frequently treated with a short flare-up protocol of GnRH (2.5%). None of the patients had to discontinue ganirelix agonist (Frydman et al., 1988) . treatment because of a hypersensitivity reaction or because of
Comparison of the number and size of follicles indicated a drug-related adverse experience.
that, in the ganirelix group, initial follicular growth was faster but the final cohort of growing follicles was smaller and Discussion produced on average less oestradiol, which is explained by the different endocrine status of the patient at the start of The ganirelix regimen is a new treatment option for patients undergoing ovarian stimulation, which largely reduces the stimulation. In view of this different follicular pattern, rFSH dose adjustments in patients treated with the ganirelix regimen duration of GnRH analogue treatment and prevents adverse events related to flare-up or down-regulation induced by GnRH should be based on the number and size of growing follicles, rather than on the amount of circulating oestradiol. The smaller in this study) in patients treated with human menopausal gonadotrophin (HMG) and 0.25 mg GnRH antagonist cetrorelix cohort of follicles and the lower oestradiol concentrations are in good agreement with the lower incidence (less than half) (n ϭ 188) and of 33% (cf. 32% in this study) in patients treated with the agonist (n ϭ 85). Therefore, several other of OHSS in the ganirelix group.
The possible direct effect of GnRH antagonists on follicle factors that may influence clinical outcome should be considered. For instance, study sites that participated in the previous growth, steroidogenesis, oocyte or embryo quality or implantation is of specific interest, since GnRH receptors have been ganirelix dose-finding study provided a favourable outcome more often for the ganirelix regimen compared with study identified in human granulosa-lutein cells (Latouche et al., 1989; Brus et al., 1997) , and might be present in uterine sites who participated for the first time. This indicates that some clinical experience with the new ganirelix regimen might endometrial tissue (Raga et al., 1998) , although their function and interaction with GnRH or GnRH analogues is not (yet) contribute positively to the success rate. In addition, the regimen applied has not been selected based on prospective understood (Ikeda et al., 1997) . Recent studies in vitro with human granulosa cells have demonstrated that neither ganirelix research, and further optimization of the regimen might appear beneficial. In the current applied regimen, stimulation was nor cetrorelix exert any significant action on ovarian steroidogenesis (Ortmann et al., 1999; Verbost et al., 1999) , and in started on day 2 or 3 of the follicular phase; thus serum gonadotrophin and steroid concentrations were higher than after the ganirelix dose-finding study no difference was noted in the number or size of follicles of patients treated in the six down-regulation in the reference group. High concentrations of serum hormones are especially established in patients who different dose groups (Ganirelix dose-finding study group, 1998).
receive the GnRH-agonist flare-up protocol, and these were reported to have a lower clinical pregnancy rate, which is In comparison with buserelin treatment in a long protocol, the ganirelix regimen resulted in one preovulatory follicle less thought to be related to a higher oestradiol concentration before HCG administration, and a higher production of oestradiol per and, as a consequence, one cumulus-oocyte complex less was recovered at oocyte retrieval. This difference is within the oocyte recovered (Cramer et al., 1999) . In the ganirelix group, the opposite was shown in that before HCG administration preset equivalence margin of -3 oocytes, and is thought to be related to the short regimen rather than ganirelix per se. The oestradiol concentrations were lower, and also the oestradiol production per follicle was lower in the ganirelix group than recovery of fewer oocytes is a well-described phenomenon of the short protocol of GnRH agonists in comparison with the in the buserelin group. Although in the current study neither serum LH nor oestradiol concentrations appeared to be predictlong protocol (Tan et al., 1992; Cramer et al., 1999) . Overall, the ganirelix regimen resulted in the recovery of good quality ive factors for pregnancy (Loumaye et al., 1997) , it cannot be excluded that the hormonal milieu of the current ganirelix oocytes as reflected by the percentage of metaphase II oocytes in ICSI patients (83% in each group), the high fertilization regimen is less favourable for a certain subset of patients. If so, patients might benefit from postponing HCG administration rate (62.1% in each group), and the number of good quality embryos, which was comparable with the reference group.
and allowing follicles to grow larger, or to pretreat patients with oral contraceptives which would also allow patient The latter finding suggests a higher recovery of good quality embryos in the ganirelix regimen than in the buserelin group, scheduling. Thus, further optimization of treatment, as well as clinical experience with the antagonist regimen, might further which is in good agreement with the outcome of a previous small study which compared the antagonist Nal-Glu optimize clinical outcome in the near future. Overall, it may be concluded that ganirelix introduces a new (5 mg/day) with the agonist leuprolide acetate (Minaretzis et al., 1995) . The recovery of good quality oocytes and treatment option for patients undergoing ovarian stimulation for IVF or ICSI which is safe, short and simple. The clinical embryos is further supported by the good success rates of replaced frozen embryos collected in the dose-finding study outcome was good, and the ongoing pregnancy rate was within the range of pregnancy rates of a long-protocol GnRH-agonist, of ganirelix (Kol et al., 1999) , as well as in this study.
In the current trial, on average only 2.2 embryos were the latter being supported by many years of clinical experience. replaced, which is in line with the current standard practice in several European IVF centres not to replace more than two References good quality embryos, in order to prevent multiple pregnancies.
Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses
In comparison with a large previous multi-centre study of of gonadotrophin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril., 67, [917] [918] [919] [920] [921] [922] Puregon, using the same stimulation regimen with buserelin, Albano, C., Smitz, J., Tournaye H. et al. (1999) Luteal phase and clinical the ongoing pregnancy rate per attempt was very similar to outcome after human menopausal gonadotrophin/gonadotrophin releasing the outcome of the ganirelix regimen (Out et al., 1995) . this tendency is related to chance. However, using the same pregnancy rate per transfer of 27% (compared with 25%
